NEW YORK (Reuters Health) - Valganciclovir, a prodrug of ganciclovir with increased bioavailability after oral administration, has been found in a multicenter study not to be associated with resistance mutations after prophylactic use in organ transplant recipients.
Your session will expire in 8 hours requiring you to log in each day to view content.
FEBRUARY 17, 2012